Nexien BioPharma, Inc. (NXEN) Financial Statements (2026 and earlier)

Company Profile

Business Address 4340 E KENTUCKY AVE
GLENDALE, CO 80246
State of Incorp. DE
Fiscal Year End June 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)
Annual | Quarterly

3/31/2025
MRQ
6/30/2024
6/30/2023
6/30/2022
6/30/2021
6/30/2020
6/30/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4,18335,147116,89818,04110,786146,356
Cash and cash equivalent4,18335,147116,89818,04110,786146,356
Prepaid expense  7,9807,6207,500  
Other current assets     12,00064,647
Other undisclosed current assets      99,667
Total current assets:4,18343,127124,51825,54122,786310,670
Noncurrent Assets
TOTAL ASSETS:4,18343,127124,51825,54122,786310,670
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:53,17823,64320,3956,37517,15144,750
Other undisclosed accounts payable and accrued liabilities53,17823,64320,3956,37517,15144,750
Debt   142,18012,94112,000 
Due to related parties✕✕ 60,75020,000  
Other undisclosed current liabilities312,254271,49118,798   
Total current liabilities:365,432295,134242,12339,31629,15144,750
Noncurrent Liabilities
Total liabilities:365,432295,134242,12339,31629,15144,750
Equity
Equity, attributable to parent, including:(361,249)(252,007)(117,605)(13,775)(6,365)265,920
Common stock7,0476,4026,0525,5775,3985,351
Additional paid in capital11,166,17710,986,20110,759,05110,476,00411,583,15911,505,819
Accumulated deficit(11,534,473)(11,295,360)(10,933,458)(10,307,101)(8,447,159)(5,775,542)
Other undisclosed equity, attributable to parent  50,75050,750(188,255)(3,147,763)(5,469,708)
Total equity:(361,249)(252,007)(117,605)(13,775)(6,365)265,920
TOTAL LIABILITIES AND EQUITY:4,18343,127124,51825,54122,786310,670

Income Statement (P&L) (USD)
Annual | Quarterly

3/31/2025
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
6/30/2020
6/30/2019
Operating expenses(155,663)(282,608)(563,992)(1,843,767)(2,671,584)(4,300,913)
Operating loss:(155,663)(282,608)(563,992)(1,843,767)(2,671,584)(4,300,913)
Nonoperating expense
(Other Nonoperating expense)		(83,450)(79,294)(62,365)(16,175)(33) 
Interest and debt expense (35,287)(29,531)(17,945)(3,234)(33) 
Loss from continuing operations:(274,400)(391,433)(644,302)(1,863,176)(2,671,650)(4,300,913)
Loss before gain (loss) on sale of properties:✕✕✕(644,302)(1,863,176)(2,671,650)(4,300,913)
Net loss:(274,400)(391,433)(644,302)(1,863,176)(2,671,650)(4,300,913)
Other undisclosed net income attributable to parent 35,28729,53117,9453,23433 
Net loss available to common stockholders, diluted:(239,113)(361,902)(626,357)(1,859,942)(2,671,617)(4,300,913)

Comprehensive Income (USD)
Annual | Quarterly

3/31/2025
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
6/30/2020
6/30/2019
Net loss:(274,400)(391,433)(644,302)(1,863,176)(2,671,650)(4,300,913)
Comprehensive loss, net of tax, attributable to parent:(274,400)(391,433)(644,302)(1,863,176)(2,671,650)(4,300,913)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: